[Corrections] Correction to 2016; 17: 727–37

19:09 EDT 29 Jul 2017 | The Lancet

Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016; 17: 727–37—In Figure 1 of this Article, the number of patients who withdrew after randomisation should have been 1 in the delayed ADT group and 2 in the immediate ADT group. This correction has been made to the online version as of July 28, 2017.

Original Article: [Corrections] Correction to 2016; 17: 727–37


More From BioPortfolio on "[Corrections] Correction to 2016; 17: 727–37"

Quick Search

Relevant Topic

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...